Michael Sedlacek, MD
Psychiatry · Omaha, NENPI 1477546372
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Eli Lilly at 50.1% of the total. Among psychiatry clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $109.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$7K
- AbbVie$6K
- Otsuka America Pharmaceutical, Inc.$255
- Teva Pharmaceuticals USA, Inc.$171
- Takeda Pharmaceuticals U.S.A., Inc.$163
- Lundbeck LLC$162
- plus $791 from 16 others
What the payments were for
- Consulting fees$7,30049%
- Speaking & faculty fees$5,32036%
- Travel & lodging$2622%
- Food & beverage$1,72812%
- Education$2181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $7,422 |
| AbbVie(2 entities) | 35 | $5,864 |
| Otsuka America Pharmaceutical, Inc. | 16 | $255 |
| Teva Pharmaceuticals USA, Inc. | 2 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $163 |
| Lundbeck LLC | 13 | $162 |
| Johnson & Johnson | 9 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $126 |
| Shire North American Group Inc | 11 | $110 |
| Sunovion Pharmaceuticals Inc. | 5 | $82 |
| Ironshore Pharmaceuticals Inc. | 3 | $51 |
| Tris Pharma Inc | 3 | $44 |
| Neurocrine Biosciences, Inc. | 3 | $40 |
| Vertical Pharmaceuticals, LLC | 3 | $37 |
| Neos Therapeutics, LP | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Amgen | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$5,467
How this compares
$14,829 in reported general payments places this provider in the 90th percentile of 160 psychiatry providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 23 | $50,364 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $10,324 |
| Paliperidone ErPaliperidone | 30 | $7,126 |
| Clozapine | 104 | $6,809 |
| Lurasidone Hcl | 11 | $6,736 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 183 | $3,779 |
| Gabapentin | 166 | $3,391 |
| Dextroamphetamine Sulfate | 12 | $3,361 |
| Lisdexamfetamine Dimesylate | 19 | $3,288 |
| Aripiprazole | 128 | $2,958 |
| Quetiapine Fumarate | 180 | $2,879 |
| Ziprasidone Hcl | 31 | $2,773 |
| Bupropion Hcl SrBupropion Hcl | 134 | $2,712 |
| Duloxetine Hcl | 148 | $2,631 |
| Lamotrigine | 284 | $2,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $145 | $50,36423 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $163 | $10,32425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Omaha
- Vithyalakshmi SelvarajOmaha$1.2M
- Sarit HovavOmaha$307K
- Mary Jo HaniganOmaha$119K
- Yon ChongOmaha$59K
- Syed SattarOmaha$16K
- Sriram RamaswamyOmaha$13K
- Elizabeth FitzpatrickOmaha$10K
- Praveen FernandesOmaha$5K
- Natalie BakerOmaha$4K
- Michael EggerOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.